#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to counsel patients that combined cannabis and tobacco use may cause structural brain changes, particularly in areas associated with memory and decision-making, which could have implications for cognitive function and mental health outcomes. This evidence should inform substance use screening and intervention discussions, especially for patients who smoke both substances recreationally or who may be at risk for cognitive decline. Patients should be educated that the additive risks of dual use differ from using either substance alone, supporting more targeted harm reduction and cessation strategies in clinical practice.
A recent neuroimaging study found that both cannabis and tobacco smoking are associated with reduced brain volume in specific regions, including areas involved in memory, decision-making, and emotional regulation. The research demonstrates dose-dependent and duration-dependent effects, with heavier or longer-term users showing greater volumetric changes compared to non-users. These structural brain changes may have clinical implications for cognitive function, mental health outcomes, and long-term neurological health, particularly in younger users whose brains are still developing. Clinicians should be aware of these findings when counseling patients about cannabis use, especially regarding inhalation methods and frequency of use. For patients considering or currently using cannabis therapeutically, discussing alternative delivery methods such as oral or sublingual formulations may help minimize potential neurotoxic exposure while maintaining therapeutic benefit.
“When patients come to me asking about cannabis, I tell them what the evidence actually shows: combustion of any plant material, whether cannabis or tobacco, exposes your lungs and brain to harmful byproducts, and the neuroimaging data on structural brain changes is concerning enough that we should be counseling people to use non-smoked delivery methods if they’re going to use cannabis at all.”
🧠 While emerging neuroimaging studies suggest associations between cannabis and tobacco smoking with reduced brain volume in specific regions, clinicians should interpret these findings cautiously given the cross-sectional nature of much current research, the difficulty in isolating cannabis effects from confounding factors like alcohol use and socioeconomic stress, and uncertainty about the clinical significance of observed volumetric changes. The mechanisms underlying any structural brain changes remain incompletely understood, and it is unclear whether modest volume reductions translate to measurable cognitive or functional decline in individual patients. Nevertheless, these findings add to growing evidence that regular cannabis use, particularly smoking as a delivery method, may carry neurobiological risks worthy of discussion during substance use screening and counseling. Clinicians should use this information to inform balanced conversations with patients about cannabis, acknowledging both potential harms and the complexity of the evidence, while emphasizing that avoiding or reducing smoking of any substance remains a reasonable harm-reduction strategy.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: